Tecfidera, Fumaderm, and Skilarence are all brand names for drugs containing the active ingredient dimethyl fumarate, while Vumerity contains the active ingredient diroximel fumarate. Differences between the drugs include chemical structures and approved uses (which also varies by country). Tecfidera
Tecfidera is approved by the FDA in the US, the EMA in the European Union, and in other markets around the world to treat relapsing forms of multiple sclerosis. It contains the active ingredient dimethyl fumarate and is taken orally twice a day (starting with 120 mg capsules for the first 7 days of treatment and 240 mg capsules thereafter). Skilarence
Skilarence is a brand name for another drug containing dimethyl fumarate. However, it is approved by the EMA for the treatment of plaque psoriasis and is not (at the time of writing) approved to treat multiple sclerosis. Skilarence has a maximum dose of 240 mg tablets taken 3 times per day, although not everyone requires this if lower doses prove effective. Fumaderm
Fumaderm is a brand name for dimethyl fumarate that also contains calcium, zinc, and magnesium salts of monoethyl fumarate. It is approved in Germany for the treatment of psoriasis. Vumerity
Vumerity is the brand name for diroximel fumarate (rather than dimethyl fumarate), produced by the same pharmaceutical company (Biogen) as Tecfidera. Although it shares chemical similarities with Tecfidera, Biogen claims that Vumerity is less likely to cause gastrointestinal side effects. Vumerity has not (at the time of writing) been approved outside of the US. Generics and biosimilars
Generic dimethyl fumarate and biosimilars (such as monomethyl fumarate, sold under the brand name Bafiertam) may also be available as alternative treatments in some countries. Other oral medications for relapsing forms of MS are also available. To get a full understanding of the options available and to help decide which is the best for you, you should speak to your doctor and MS care team.